



Adam R. Knecht, Esq.
knechta@hallevans.com
Direct: (702) 982-6800

September 28, 2023

File No. 20013-1

OTC Markets Group Inc.
304 Hudson Street, 2nd Floor
New York, NY 10013

RE: Attorney Letter Regarding Adequate Current Information of Vita Mobile Systems, Inc., trading symbol "VMSI"

Dear Sir or Madam:

Hall & Evans has acted as special counsel to Vita Mobile Systems, Inc., a Florida corporation, (the "Company"), with respect to the provisions of Rule 144(c)(2) promulgated under the Securities Act of 1933, as amended (the "Securities Act"). The Company has requested that we provide this letter to you for posting on the OTC Disclosure and News Service ("OTC News Service").

In our capacity as special counsel to the Company, we have examined such corporate records and other documents of the Company, including its Articles of Incorporation, Bylaws, and certain minutes and actions of the Company's Board of Directors and its stockholders (the "Corporate Documents") and we have made such other investigations of law and facts as we have deemed necessary to enable us to make the confirmations expressed below. We have also examined the documents listed below (the "Information"):

- The Company's OTC Pink Basic Quarterly Report and Disclosure Statement (unaudited) for the quarter ending December 31, 2022 as posted with the OTC News Services on February 16, 2023.
- The Company's OTC Pink Basic Annual Information and Disclosure Statement for the year ending December 31, 2022 ("2022 Annual Report") as posted with the OTC News Service on April 1, 2023;
- The Company's OTC Pink Basic Quarterly Report and Disclosure Statement (unaudited) for the quarter ending March 31, 2023 as posted with the OTC News Services on May 1, 2023.

- The Company's OTC Pink Basic Quarterly Report and Disclosure Statement (unaudited) for the quarter ending June 30, 2023 as posted with the OTC News Services on August 23, 2023.
- The Company's OTC Pink Basic Annual Information and Disclosure Statement for the year ending December 31, 2022 ("2022 Annual Report") as posted with the OTC News Service on September 19, 2023;
- The Company's OTC Pink Basic Quarterly Report and Disclosure Statement (unaudited) for the quarter ending March 31, 2023 as posted with the OTC News Services on September 19, 2023.
- The Company's OTC Pink Basic Quarterly Report and Disclosure Statement (unaudited) for the quarter ending June 30, 2023 as posted with the OTC News Services on September 19, 2023.

As to matters of fact, we have relied upon the Corporate Documents, the Information, and such other information provided by the officers and directors of the Company and the Company's transfer agent as we deemed relevant. The undersigned counsel has also met with certain of the Company's officers and directors, telephonically, specifically Martin R. Wade, the Company's Chairman of the Board and Chief Financial Officer. In such telephone conversations the Information, the Corporate Documents, and other information as provided by the Company were discussed. We have no reason to believe that such information, documents, and records from all sources as provided to us are not accurate, authentic, and reliable.

The confirmations and statements expressed herein are limited solely to the federal law of the United States and the law of the State of Nevada.

Based upon the foregoing and subject to our stated assumptions, qualifications and limitations, we confirm that:

The Company's financial statements have been prepared by Mr. Wade. The Company's financial statements have not been audited. Mr. Wade has extensive experience in business and finance, and holds a B.S. degree in Business Administration from West Virginia University as well as a M.B.A. degree from the University of Wyoming.

The Company's transfer agent is Empire Stock Transfer, whose address is 1859 Whitney Mesa Dr., Henderson, NV 89014. We have confirmed that the transfer agent is registered as a transfer agent with the Securities and Exchange Commission (the "SEC"). The number of outstanding shares as set forth in the 2019 Annual Report was confirmed by review of a stockholder list as provided by the transfer agent, and by reconciling the matters pending as of December 31, 2019 not reflected on the stockholder list.

The Information (a) constitutes “adequate current public information” concerning the Company’s common stock as quoted on the OTC Link (the “Securities”), and “is available” within the meaning of Rule 144(c)(2) of the Securities Act, (b) includes all the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the Securities pursuant to Rule 15c2-11 of the Securities Exchange Act of 1934, as amended, (c) complies as to form with the OTC Markets Group’s OTC Risk Disclosure Guidelines for Providing Adequate Current Information, available at www.otcmarkets.com, and (d) has been posted through the OTC News Service.

To the best of our knowledge, after inquiry of management and the directors of the Company, we confirm that neither our firm, nor the Company, nor any 5% or more holder of the Securities is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws. Furthermore, after inquiry of management and the directors of the Company, neither the Company, nor its predecessors, is or ever was a “shell company” as defined in Rules 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934.

The confirmations and statements made in the letter are subject to the following assumptions, exceptions, and qualifications:

(a) We have assumed that (i) all information in all documents reviewed by us is true and correct, (ii) all signatures on all documents reviewed by us are genuine, (iii) all documents submitted to us as originals are true and complete, (iv) all documents submitted to us as copies are true and complete copies of the originals thereof, and (v) each natural person signing any document reviewed by us had the legal capacity to do so.

(b) Except as specifically set forth herein, we have made no independent investigation as to the accuracy or completeness of any factual matters contained in the records, documents and certificates that we have reviewed in connection with the foregoing opinion.

(c) We make no statement or confirmation with respect to the financial statements and schedules and other financial and accounting information and data other than the confirmations expressly set forth above, and no opinion, statement, or confirmation on any other matter may be inferred or implied from this letter.

(d) We make no statement or confirmation as to any matter other than the confirmations expressly set forth above, and no opinion, statement, or confirmation on any other matter may be inferred or implied from this letter.

(e) The confirmations expressed herein are given as of the date of this letter, and we disclaim any obligation to advise you of any change in any matter set forth herein.

...


The undersigned counsel makes the following representations:

- (a) is a resident of the United States;
- (b) is licensed to practice law and in good standing in States of Nevada, Utah, and New Mexico;
- (c) is permitted to practice before the SEC; has not been prohibited from practice before the SEC;
- (d) has not received, nor has an agreement to receive in the future, shares of the Company's stock, in payment for services;
- (e) is not currently, nor has in the past five years, been the subject of an investigation, hearing, or proceeding by the SEC, the U.S. Commodity Futures Trading Commission (CFTC), the Financial Industry Regulatory Authority (FINRA), or any other federal, state, or foreign regulatory agency
- (f) is not currently, nor has been in the past five years, suspended or barred from practicing in any state or jurisdiction, nor has been charged in a civil or criminal case.

No person or entity other than the OTC Markets Group is entitled to rely upon this letter for any purpose. OTC Markets Group is granted permission and rights to publish this letter via the OTC News Service for viewing by the public and applicable regulators.

Very truly yours,

HALL & EVANS LLC



Adam R. Knecht, Esq.